Biopharmaceutical Company
Appears in 1 story · Last updated Jun 13, 2026
As of June 2026: Phase 1 complete in 88 participants with no dose-limiting toxicities; Phase 2b sarcopenia enrollment planned H2 2026; FDA Fast Track Designation application due Q2 2026 (decision pending); preclinical IBD program (MF-300 and MF-1305) active
A November 2025 study in Science showed that blocking an enzyme called 15-PGDH regrew cartilage in older mice and in human joint tissue from knee replacement patients. Blocking it shifts cartilage cells from degrading to rebuilding—without stem cells.
Updated Jun 13
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
